Investigation of critical factors for the resolution of SR695, a key impurity, from efavirenz in the reversed-phase assay of efavirenz dosage forms.
An investigation of the critical factors effecting the resolution of SR695 from efavirenz in the assay of efavirenz by reversed-phase HPLC was performed. This study was implemented to address the inability of a subset of the Zorbax SB-CN columns used in this method to adequately perform this separation, which were otherwise indistinguishable from columns of this type that could. In this study, column temperature, detector time-constant, pre-gradient isocratic hold-time, pre-column mixing volume, column, and HPLC type were considered. Experimental Design methods were employed to find the relative importance of these factors and to find parameters that would optimize the resolution of SR695 and efavirenz on any HPLC, with any column of this type, for both efavirenz oral liquid and capsule samples. It was also desired that this method change be minimal, so that extensive revalidation would not be required. The most important factors were the column temperature, with lower temperatures giving better resolution, and pre-column mixing volume of sample with mobile phase, with higher mixing volumes giving better resolution up to an asymptote reached at around 150 microl. Added pre-gradient isocratic hold time was found to result in a small improvement in resolution, but was insignificant compared with the other factors mentioned above. A possible explanation is given for the mechanism by which temperature and pre-column mixing have this effect on the resolution obtained in this assay.
Weissburg
Robert P
RP
DuPont Pharmaceuticals Company, Experimental Station, Wilmington, DE 19880-0353, USA. robert.p.weissburg@dupontpharma.com
Montgomery
Eda Ross
ER
Junnier
Lisa A
LA
Segretario
Jim
J
Cook
Stacy
S
Hovsepian
Paul K
PK
D000480:Alkynes; D048588:Benzoxazines; D002214:Capsules; D002851:Chromatography, High Pressure Liquid / Q000295:instrumentation / Q000379:methods; D003521:Cyclopropanes; D004304:Dosage Forms; D004340:Drug Contamination / Q000517:prevention & control*; D004353:Drug Evaluation, Preclinical; D010078:Oxazines / Q000032:analysis* / Q000737:chemistry / Q000378:metabolism; D019999:Pharmaceutical Solutions; D018894:Reverse Transcriptase Inhibitors / Q000032:analysis / Q000737:chemistry; D013696:Temperature
D000480:Alkynes; D048588:Benzoxazines; D002214:Capsules; D003521:Cyclopropanes; D004304:Dosage Forms; D010078:Oxazines; D019999:Pharmaceutical Solutions; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz